We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+5.06%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.8B
AUM Growth
+$261M
Cap. Flow
+$368M
Cap. Flow %
3.12%
Top 10 Hldgs %
80.71%
Holding
127
New
5
Increased
21
Reduced
20
Closed
13

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$268M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$210M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$46.6M
4
HRTX icon
Heron Therapeutics
HRTX
+$44.6M
5
ACGN
Aceragen Inc
ACGN
+$41M

Top Sells

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$98.3M
2
RXDX
Ignyta, Inc.
RXDX
+$37M
3
IMGN
Immunogen Inc
IMGN
+$16.4M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$10.8M
5
ANAB icon
AnaptysBio
ANAB
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.85%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TTOO
101
DELISTED
T2 Biosystems, Inc
TTOO
$649K 0.01%
20
– –
AKTX
102
Akari Therapeutics
AKTX
$14.4M
$618K 0.01%
425
-446
-51% -$963K
MTEM
103
DELISTED
Molecular Templates, Inc.
MTEM
$579K ﹤0.01%
4,827
– –
FLGT icon
104
Fulgent Genetics
FLGT
$558M
$500K ﹤0.01%
125,000
– –
IMDZ
105
DELISTED
Immune Design Corp.
IMDZ
$491K ﹤0.01%
148,937
– –
BDSI
106
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$473K ﹤0.01%
210,021
– –
BGMSP
107
DELISTED
Bio Green Med Solution Inc Preferred Stock
BGMSP
$77K ﹤0.01%
13,253
– –
BTX.WS
108
DELISTED
BioTime Inc Warrants (Expiring October 1, 2018)
BTX.WS
$2K ﹤0.01%
20,084
– –
AGIO icon
109
Agios Pharmaceuticals
AGIO
$2.08B
– –
-128,666
Closed -$7.36M
KPTI icon
110
Karyopharm Therapeutics
KPTI
$155M
– –
-14,466
Closed -$2.08M
LGND icon
111
Ligand Pharmaceuticals
LGND
$5.77B
– –
-117,638
Closed -$10M
TENX icon
112
Tenax Therapeutics
TENX
$393M
– –
-11
Closed -$171K
ITCI
113
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-609,166
Closed -$8.82M
IMGN
114
DELISTED
Immunogen Inc
IMGN
– –
-2,563,489
Closed -$16.4M
ACOR
115
DELISTED
Acorda Therapeutics
ACOR
– –
-1,716
Closed -$4.42M
EPZM
116
DELISTED
Epizyme, Inc
EPZM
– –
-232,481
Closed -$2.92M
FPRX
117
DELISTED
Five Prime Therapeutics, Inc.
FPRX
– –
-19,247
Closed -$422K
AKAO
118
DELISTED
Achaogen Inc
AKAO
– –
-122,482
Closed -$1.31M
NVIV
119
DELISTED
InVivo Therapeutics Holdings Corp
NVIV
– –
-18
Closed -$255K
AAAP
120
DELISTED
Advanced Accelerator Applications S.A.
AAAP
– –
-55,125
Closed -$4.5M
RXDX
121
DELISTED
Ignyta, Inc.
RXDX
– –
-1,384,266
Closed -$37M
1 2 3 4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2018 Portfolio in Review

As of Q1 2018, Baker Bros. Advisors held 127 positions worth $11.8B, up 2.3% from $11.5B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Baker Bros. Advisors deployed $368M of net new capital in Q1 2018, opening 5 new positions and adding to 21 existing holdings. Its largest new stake was VYNE Therapeutics: 194 shares worth $26.3M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Ablynx NV, an estimated $98.3M trimmed.

  • Baker Bros. Advisors's largest Q1 2018 buy was VYNE Therapeutics: 194 shares worth $26.3M.
  • Baker Bros. Advisors added most to BeOne Medicines Ltd in Q1 2018, an estimated $268M increase.
  • Baker Bros. Advisors's biggest Q1 2018 reduction was Ablynx NV, cutting an estimated $98.3M.
  • Baker Bros. Advisors fully exited Ignyta, Inc. in Q1 2018, selling an estimated $37M.
  • Baker Bros. Advisors's ten largest holdings make up 81% of its $11.8B portfolio in Q1 2018.
  • Baker Bros. Advisors opened 5 new positions and closed 13 in Q1 2018.
  • Baker Bros. Advisors's portfolio value rose 2.3% quarter-over-quarter to $11.8B.

Based on Baker Bros. Advisors's 13F filing for Q1 2018, filed 15 May 2018.